Targeting MSR1+ tumor-associated macrophages enhances the therapeutic efficacy of anti-PD-L1 in hepatocellular carcinoma by suppressing NF-κB pathway activation
Cancer Letters · 2026-06 · 647 · 218449
DOI: 10.1016/j.canlet.2026.218449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-06. Verfasst von Jianpeng Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangz…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Tumor-Associated Macrophages, NF-kappa B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China-Shandong Joint Fund for Marine Science Research Centers, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
MSR1+ tumor-associated macrophages (TAMs) have been implicated in various malignancies; however, their functional role in Hepatocellular carcinoma (HCC) remains poorly defined. This research seeks to clarify the roles of MSR1+ TAMs in HCC and their influence on the tumor immune microenvironment. Clinical and experimental data indicate that high levels of MSR1+ TAMs correlate with poor prognosis in HCC patients. Transcriptomic analyses and in vitro as well as in vivo functional assays revealed that the immunosuppressive activity of MSR1+ TAMs is closely linked to their secretory profile. MSR1 enhances IL-6 secretion by activating the NF-κB signaling pathway, subsequently facilitating the recruitment of myeloid-derived suppressor cells (MDSCs). This cascade diminishes CD8+ T cell infiltration and effector function, promoting an immunosuppressive tumor microenvironment. In preclinical models, the simultaneous inhibition of MSR1 and PD-L1 markedly reduced tumor growth more effectively than either treatment alone. Our findings demonstrate that MSR1+ TAMs contribute to hepatocellular carcinogenesis through the NF-κB/IL-6 signaling axis by promoting MDSCs accumulation and impairing CD8+ T cell responses. Effectively targeting MSR1+ TAMs can overcome resistance to anti-PD-L1 therapy, offering a promising new immunotherapeutic approach for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China; NHC Key Laboratory of Combined Multi-organ Transpl…
- Department of Hepatobiliary and Pancreatic Surgery, Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren…
Förderung
- National Natural Science Foundation of China-Shandong Joint Fund for Marine Science Research Centers
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences
- National Key Research and Development Program of China
- Primary Research and Development Plan of Zhejiang Province
- Major Science and Technology Project of Hainan Province
Zitieren
APA
Liu, J., Liu, X., Li, Z., Yu, X., Qian, J., Zhang, Z., Ding, X., Su, R., Mao, J., Luo, X., Wang, S., Xie, Q., Xie, H., Yin, S., Zhou, L., Yang, Z., & Zheng, S. (2026). Targeting MSR1+ tumor-associated macrophages enhances the therapeutic efficacy of anti-PD-L1 in hepatocellular carcinoma by suppressing NF-κB pathway activation. Cancer Letters, 647, 218449. https://doi.org/10.1016/j.canlet.2026.218449
Vancouver
Liu J, Liu X, Li Z, Yu X, Qian J, Zhang Z, et al. Targeting MSR1+ tumor-associated macrophages enhances the therapeutic efficacy of anti-PD-L1 in hepatocellular carcinoma by suppressing NF-κB pathway activation. Cancer Letters. 2026;647:218449. doi:10.1016/j.canlet.2026.218449
BibTeX
@article{Liu2026,
author = {Liu, Jianpeng and Liu, Xi and Li, Zekuan and Yu, Xizhi and Qian, Junjie and Zhang, Zhihao and Ding, Xinjiang and Su, Rong and Mao, Jing and Luo, Xingyu and Wang, Shuo and Xie, Qinfen and Xie, Haiyang and Yin, Shengyong and Zhou, Lin and Yang, Zhe and Zheng, Shusen},
title = {Targeting MSR1+ tumor-associated macrophages enhances the therapeutic efficacy of anti-PD-L1 in hepatocellular carcinoma by suppressing NF-κB pathway activation},
journal = {Cancer Letters},
year = {2026},
volume = {647},
pages = {218449},
doi = {10.1016/j.canlet.2026.218449}
}
EUVIMED